The Regulation and Interactions of the Hypoxia Inducible Factor Pathway in Carcinogenesis and Potential Cancer Therapeutic Strategies


The Hypoxia Inducible factor (HIF) pathway is known to be constitutionally active in various cancers and is the dominant pathway in some cancers such as VHL mutant clear cell Renal cell carcinoma. HIF-1α and HIF-2α overexpression is known to be important for tumor cell proliferation, maintenance of stemness and angiogenesis. There has been growing interest in therapeutic strategies targeting the HIF pathway over the last decade. We review in this section the role of hypoxia inducible factor pathway in carcinogenesis, its crosstalk with other pathways and potential cancer therapeutic strategies targeting the HIF pathway, its upstream regulators and downstream signaling.

Share and Cite:

Shenoy, N. , Shrivastava, M. , Sukrithan, V. , Papaspyridi, D. and Darbinyan, K. (2015) The Regulation and Interactions of the Hypoxia Inducible Factor Pathway in Carcinogenesis and Potential Cancer Therapeutic Strategies. Journal of Cancer Therapy, 6, 511-521. doi: 10.4236/jct.2015.66055.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Semenza, G.L. (2013) HIF-1 Mediates Metabolic Responses to Intratumoral Hypoxia and Oncogenic Mutations. The Journal of Clinical Investigation, 123, 3664-3671.
[2] Jiang, B.H. and Liu, L.Z. (2008) AKT Signaling in Regulating Angiogenesis. Current Cancer Drug Targets, 8, 19-26.
[3] Joshi, S., Singh, A.R., Zulcic, M. and Durden, D.L. (2014) A Macrophage-Dominant PI3K Isoform Controls Hypoxia-Induced HIF1alpha and HIF2alpha Stability and Tumor Growth, Angiogenesis, and Metastasis. Molecular Cancer Research, 12, 1520-1531.
[4] Fang, J., Ding, M., Yang, L., Liu, L.Z. and Jiang, B.H. (2007) PI3K/PTEN/AKT Signaling Regulates Prostate Tumor ANGIOGENESIS. Cell Signal, 19, 2487-2497.
[5] Zhong, H., Chiles, K., Feldser, D., Laughner, E., Hanrahan, C., Georgescu, M.M., et al. (2000) Modulation of Hypoxia-Inducible Factor 1alpha Expression by the Epidermal Growth Factor/Phosphatidylinositol 3-kinase/PTEN/AKT/ FRAP Pathway in human Prostate Cancer Cells: Implications for Tumor Angiogenesis and Therapeutics. Cancer Research, 60, 1541-1545.
[6] Laughner, E., Taghavi, P., Chiles, K., Mahon, P.C. and Semenza, G.L. (2001) HER2 (neu) Signaling Increases the Rate of Hypoxia-Inducible Factor 1alpha (HIF-1alpha) Synthesis: Novel Mechanism for HIF-1-Mediated Vascular Endothelial Growth Factor Expression. Molecular and Cellular Biology, 21, 3995-4004.
[7] Pore, N., Jiang, Z., Shu, H.K., Bernhard, E., Kao, G.D. and Maity, A. (2006) Akt1 Activation Can Augment Hypoxia-Inducible Factor-1alpha Expression by Increasing Protein Translation through a Mammalian Target of Rapamycin-Independent Pathway. Molecular Cancer Research, 4, 471-479.
[8] Li, W., Qiu, T., Zhi, W., Shi, S., Zou, S., Ling, Y., et al. (2015) Colorectal Carcinomas with KRAS Codon 12 Mutation Are Associated with More Advanced Tumor Stages. BMC Cancer, 15, 340.
[9] Kikuchi, H., Pino, M.S., Zeng, M., Shirasawa, S. and Chung, D.C. (2009) Oncogenic KRAS and BRAF Differentially Regulate Hypoxia-Inducible Factor-1α and -2α in Colon Cancer. Cancer Research, 69, 8499-8506.
[10] Kang, R., Hou, W., Zhang, Q., Chen, R., Lee, Y.J., Bartlett, D.L., et al. (2014) RAGE Is Essential for Oncogenic KRAS-Mediated Hypoxic Signaling in Pancreatic Cancer. Cell Death & Disease, 5, e1480.
[11] Sun, H.L., Liu, Y.N., Huang, Y.T., Pan, S.L., Huang, D.Y., Guh, J.H., et al. (2007) YC-1 Inhibits HIF-1 Expression in Prostate Cancer Cells: Contribution of Akt/NF-KappaB Signaling to HIF-1Alpha Accumulation during Hypoxia. Oncogene, 26, 3941-3951.
[12] Kondo, K. and Kaelin Jr., W.G. (2001) The von Hippel-Lindau Tumor Suppressor Gene. Experimental Cell Research, 264, 117-125.
[13] Haase, V.H. (2006) The VHL/HIF Oxygen-Sensing Pathway and Its Relevance to Kidney Disease. Kidney International, 69, 1302-1307.
[14] Pugh, C.W. and Ratcliffe, P.J. (2003) The von Hippel-Lindau Tumor Suppressor, Hypoxia-Inducible Factor-1 (HIF-1) Degradation, and Cancer Pathogenesis. Seminars in Cancer Biology, 13, 83-89.
[15] Esteban, M.A., Tran, M.G., Harten, S.K., Hill, P., Castellanos, M.C., Chandra, A., et al. (2006) Regulation of E-Cadherin Expression by VHL and Hypoxia-Inducible Factor. Cancer Research, 66, 3567-3575.
[16] Russell, R.C. and Ohh, M. (2007) The Role of VHL in the Regulation of E-Cadherin: A New Connection in an Old Pathway. Cell Cycle, 6, 56-59.
[17] Krishnamachary, B., Zagzag, D., Nagasawa, H., Rainey, K., Okuyama, H., Baek, J.H., et al. (2006) Hypoxia-Inducible Factor-1-Dependent Repression of E-Cadherin in von Hippel-Lindau Tumor Suppressor-Null Renal Cell Carcinoma Mediated by TCF3, ZFHX1A, and ZFHX1B. Cancer Research, 66, 2725-2731.
[18] Evans, A.J., Russell, R.C., Roche, O., Burry, T.N., Fish, J.E., Chow, V.W., et al. (2007) VHL Promotes E2 Box-Dependent E-Cadherin Transcription by HIF-Mediated Regulation of SIP1 and Snail. Molecular and Cellular Biology, 27, 157-169.
[19] Sermeus, A. and Michiels, C. (2011) Reciprocal Influence of the p53 and the Hypoxic Pathways. Cell Death Disease, 2, e164.
[20] Chen, D., Li, M., Luo, J. and Gu, W. (2003) Direct Interactions between HIF-1Alpha and Mdm2 Modulate p53 Function. The Journal of Biological Chemistry, 278, 13595-81359.
[21] Hammond, E.M., Mandell, D.J., Salim, A., Krieg, A.J., Johnson, T.M., Shirazi, H.A., et al. (2006) Genome-Wide Analysis of p53 under Hypoxic Conditions. Molecular and Cellular Biology, 26, 3492-3504.
[22] Ravi, R., Mookerjee, B., Bhujwalla, Z.M., Sutter, C.H., Artemov, D., Zeng, Q., et al. (2000) Regulation of Tumor Angiogenesis by p53-Induced Degradation of Hypoxia-Inducible Factor 1Alpha. Genes Development, 14, 34-44.
[23] Sumiyoshi, Y., Kakeji, Y., Egashira, A., Mizokami, K., Orita, H. and Maehara, Y. (2006) Overexpression of Hypoxia-Inducible Factor 1Alpha and p53 Is a Marker for an Unfavorable Prognosis in Gastric Cancer. Clinical Cancer Research, 12, 5112-5117.
[24] Kamat, C.D., Green, D.E., Warnke, L., Thorpe, J.E., Ceriello, A. and Ihnat, M.A. (2007) Mutant p53 Facilitates Pro-Angiogenic, Hyperproliferative Phenotype in Response to Chronic Relative Hypoxia. Cancer Letters, 249, 209-219.
[25] Xu, Y., Li, Y., Pang, Y., Ling, M., Shen, L., Yang, X., et al. (2012) EMT and Stem Cell-Like Properties Associated with HIF-2Alpha Are Involved in Arsenite-Induced Transformation of Human Bronchial Epithelial Cells. PLoS ONE, 7, e37765.
[26] Higgins, D.F., Kimura, K., Bernhardt, W.M., Shrimanker, N., Akai, Y., Hohenstein, B., et al. (2007) Hypoxia Promotes Fibrogenesis in Vivo via HIF-1 Stimulation of Epithelial-to-Mesenchymal Transition. The Journal of Clinical Investigation, 117, 3810-3820.
[27] Mimeault, M. and Batra, S.K. (2013) Hypoxia-Inducing Factors as Master Regulators of Stemness Properties and Altered Metabolism of Cancer- and Metastasis-Initiating Cells. Journal of Cellular and Molecular Medicine, 17, 30-54.
[28] Du, R., Xia, L., Ning, X., Liu, L., Sun, W., Huang, C., et al. (2014) Hypoxia-Induced Bmi1 Promotes Renal Tubular Epithelial Cell-Mesenchymal Transition and Renal Fibrosis via PI3K/Akt Signal. Molecular Biology of the Cell, 25, 2650-2659.
[29] Guo, B.H., Feng, Y., Zhang, R., Xu, L.H., Li, M.Z., Kung, H.F., et al. (2011) Bmi-1 Promotes Invasion and Metastasis, and Its Elevated Expression Is Correlated with an Advanced Stage of Breast Cancer. Molecular Cancer, 10, 10.
[30] Yang, M.H., Hsu, D.S., Wang, H.W., Wang, H.J., Lan, H.Y., Yang, W.H., et al. (2010) Bmi1 Is Essential in Twist1-Induced Epithelial-Mesenchymal Transition. Nature Cell Biology, 12, 982-992.
[31] Song, L.B., Li, J., Liao, W.T., Feng, Y., Yu, C.P., Hu, L.J., et al. (2009) The Polycomb Group Protein Bmi-1 Represses the Tumor Suppressor PTEN and Induces Epithelial-Mesenchymal Transition in Human Nasopharyngeal Epithelial Cells. The Journal of Clinical Investigation, 119, 3626-3636.
[32] Sun, S., Ning, X., Zhang, Y., Lu, Y., Nie, Y., Han, S., et al. (2009) Hypoxia-Inducible Factor-1alpha Induces Twist Expression in Tubular Epithelial Cells Subjected to Hypoxia, Leading to Epithelial-to-Mesenchymal Transition. Kidney International, 75, 1278-1287.
[33] Chang, L.H., Chen, C.H., Huang, D.Y., Pai, H.C., Pan, S.L. and Teng, C.M. (2011) Thrombin Induces Expression of Twist and Cell Motility via the Hypoxia-Inducible Factor-1Alpha Translational Pathway in Colorectal Cancer Cells. Journal of Cellular Physiology, 226, 1060-1068.
[34] Wu, C.Y., Hung, J.J. and Wu, K.J. (2012) Linkage between Twist1 and Bmi1: Molecular Mechanism of Cancer Metastasis/Stemness and Clinical Implications. Clinical and Experimental Pharmacology and Physiology, 39, 668-673.
[35] Wu, K.J. and Yang, M.H. (2011) Epithelial-Mesenchymal Transition and Cancer Stemness: The Twist1-Bmi1 Connection. Bioscience Reports, 31, 449-455.
[36] Wu, K.J. (2011) Direct Activation of Bmi1 by Twist1: Implications in Cancer Stemness, Epithelial-Mesenchymal Transition, and Clinical Significance. Chang Gung Medical Journal, 34, 229-238.
[37] Liu, S., Dontu, G., Mantle, I.D., Patel, S., Ahn, N.S., Jackson, K.W., et al. (2006) Hedgehog Signaling and Bmi-1 Regulate Self-Renewal of Normal and Malignant Human Mammary Stem Cells. Cancer Research, 66, 6063-6071.
[38] Copple, B.L. (2010) Hypoxia Stimulates Hepatocyte Epithelial to Mesenchymal Transition by Hypoxia-Inducible Factor and Transforming Growth Factor-Beta-Dependent Mechanisms. Liver International, 30, 669-682.
[39] Han, W.Q., Zhu, Q., Hu, J., Li, P.L., Zhang, F. and Li, N. (2013) Hypoxia-Inducible Factor Prolyl-Hydroxylase-2 Mediates Transforming Growth Factor Beta1-Induced Epithelial-Mesenchymal Transition in Renal Tubular Cells. Biochimica et Biophysica Acta, 1833, 1454-1462.
[40] Basu, R.K., Hubchak, S., Hayashida, T., Runyan, C.E., Schumacker, P.T. and Schnaper, H.W. (2011) Interdependence of HIF-1Alpha and TGF-Beta/Smad3 Signaling in Normoxic and Hypoxic Renal Epithelial Cell Collagen Expression. Renal Physiology—American Journal of Physiology, 300, F898-F905.
[41] Bai, H., Ge, S., Lu, J., Qian, G. and Xu, R. (2013) Hypoxia Inducible Factor-1Alpha-Mediated Activation of Survivin in Cervical Cancer Cells. Journal of Obstetrics and Gynaecology Research, 39, 555-563.
[42] Peng, X.H., Karna, P., Cao, Z., Jiang, B.H., Zhou, M. and Yang, L. (2006) Cross-Talk between Epidermal Growth Factor Receptor and Hypoxia-Inducible Factor-1Alpha Signal Pathways Increases Resistance to Apoptosis by Up-Regulating Survivin Gene Expression. The Journal of Biological Chemistry, 281, 25903-25914.
[43] Wang, Y.F., Ma, S.R., Wang, W.M., Huang, C.F., Zhao, Z.L., Liu, B., et al. (2014) Inhibition of Survivin Reduces HIF-1Alpha, TGF-Beta1 and TFE3 in Salivary Adenoid Cystic Carcinoma. PLoS ONE, 9, e114051.
[44] Chen, S., Zhang, M., Xing, L., Wang, Y., Xiao, Y. and Wu, Y. (2015) HIF-1Alpha Contributes to Proliferation and Invasiveness of Neuroblastoma Cells via SHH Signaling. PLoS ONE, 10, e0121115.
[45] Onishi, H., Morisaki, T., Nakao, F., Odate, S., Morisaki, T. and Katano, M. (2013) Protein-Bound Polysaccharide Decreases Invasiveness and Proliferation in Pancreatic Cancer by Inhibition of Hedgehog Signaling and HIF-1Alpha Pathways under Hypoxia. Cancer Letters, 335, 289-298.
[46] Lei, J., Ma, J., Ma, Q., Li, X., Liu, H., Xu, Q., et al. (2013) Hedgehog Signaling Regulates Hypoxia Induced Epithelial to Mesenchymal Transition and Invasion in Pancreatic Cancer Cells via a Ligand-Independent Manner. Molecular Cancer, 12, 66.
[47] Cejudo-Martin, P. and Johnson, R.S. (2005) A New Notch in the HIF Belt: How Hypoxia Impacts Differentiation. Developmental Cell, 9, 575-576.
[48] Irshad, K., Mohapatra, S.K., Srivastava, C., Garg, H., Mishra, S., Dikshit, B., et al. (2015) A Combined Gene Signature of Hypoxia and Notch Pathway in Human Glioblastoma and Its Prognostic Relevance. PLoS ONE, 10, e0118201.
[49] Gustafsson, M.V., Zheng, X., Pereira, T., Gradin, K., Jin, S., Lundkvist, J., et al. (2005) Hypoxia Requires Notch Signaling to Maintain the Undifferentiated Cell State. Developmental Cell, 9, 617-628.
[50] Diez, H., Fischer, A., Winkler, A., Hu, C.J., Hatzopoulos, A.K., Breier, G., et al. (2007) Hypoxia-Mediated Activation of Dll4-Notch-Hey2 Signaling in Endothelial Progenitor Cells and Adoption of Arterial Cell Fate. Experimental Cell Research, 313, 1-9.
[51] Zheng, X., Linke, S., Dias, J.M., Zheng, X., Gradin, K., Wallis, T.P., et al. (2008) Interaction with Factor Inhibiting HIF-1 Defines an Additional Mode of Cross-Coupling between the Notch and Hypoxia Signaling Pathways. Proceedings of the National Academy of Sciences of the United States of America, 105, 3368-3373.
[52] Ohh, M. (2012) Tumor Strengths and Frailties: Cancer SUMmOns Otto’s Metabolism. Nature Medicine, 18, 30-31.
[53] Busca, R., Berra, E., Gaggioli, C., Khaled, M., Bille, K., Marchetti, B., et al. (2005) Hypoxia-Inducible Factor 1Alpha Is a New Target of Microphthalmia-Associated Transcription Factor (MITF) in Melanoma Cells. The Journal of Cell Biology, 170, 49-59.
[54] Panneerselvam, J., Jin, J., Shanker, M., Lauderdale, J., Bates, J., Wang, Q., et al. (2015) IL-24 Inhibits Lung Cancer Cell Migration and Invasion by Disrupting The SDF-1/CXCR4 Signaling Axis. PLoS ONE, 10, e0122439.
[55] Mori, T., Doi, R., Koizumi, M., Toyoda, E., Ito, D., Kami, K., et al. (2004) CXCR4 Antagonist Inhibits Stromal Cell-Derived Factor 1-Induced Migration and Invasion of Human Pancreatic Cancer. Molecular Cancer Therapeutics, 3, 29-37.
[56] Wu, H., Zhu, L., Zhang, H., Shi, X., Zhang, L., Wang, W., et al. (2015) Coexpression of EGFR and CXCR4 Predicts Poor Prognosis in Resected Pancreatic Ductal Adenocarcinoma. PLoS ONE, 10, e0116803.
[57] Phillips, R.J., Mestas, J., Gharaee-Kermani, M., Burdick, M.D., Sica, A., Belperio, J.A., et al. (2005) Epidermal Growth Factor and Hypoxia-Induced Expression of CXC Chemokine Receptor 4 on Non-Small Cell Lung Cancer Cells Is Regulated by the Phosphatidylinositol 3-Kinase/PTEN/AKT/Mammalian Target of Rapamycin Signaling Pathway and Activation of Hypoxia Inducible Factor-1Alpha. The Journal of Biological Chemistry, 280, 22473-22481.
[58] Wilson, J.L., Burchell, J. and Grimshaw, M.J. (2006) Endothelins Induce CCR7 Expression by Breast Tumor Cells via Endothelin Receptor A and Hypoxia-Inducible Factor-1. Cancer Research, 66, 11802-11807.
[59] Semenza, G.L. (2010) HIF-1: Upstream and Downstream of Cancer Metabolism. Current Opinion in Genetics Development, 20, 51-56.
[60] Courtnay, R., Ngo, D.C., Malik, N., Ververis, K., Tortorella, S.M. and Karagiannis, T.C. (2015) Cancer Metabolism and the Warburg Effect: The Role of HIF-1 and PI3K. Molecular Biology Reports, 42, 841-851.
[61] Iyer, N.V., Kotch, L.E., Agani, F., Leung, S.W., Laughner, E., Wenger, R.H., et al. (1998) Cellular and Developmental Control of O2 Homeostasis by Hypoxia-Inducible Factor 1Alpha. Genes Development, 12, 149-162.
[62] Chen, C., Pore, N., Behrooz, A., Ismail-Beigi, F. and Maity, A. (2001) Regulation of glut1 mRNA by Hypoxia-Inducible Factor-1. Interaction between H-ras and Hypoxia. The Journal of Biological Chemistry, 276, 9519-9525.
[63] Sadlecki, P., Bodnar, M., Grabiec, M., Marszalek, A., Walentowicz, P., Sokup, A., et al. (2014) The Role of Hypoxia-Inducible Factor-1α, Glucose Transporter-1, (GLUT-1) and Carbon Anhydrase IX in Endometrial Cancer Patients. BioMed Research International, 2014, Article ID: 616850.
[64] Ullah, M.S., Davies, A.J. and Halestrap, A.P. (2006) The Plasma Membrane Lactate Transporter MCT4, but Not MCT1, Is Up-Regulated by Hypoxia through a HIF-1Alpha-Dependent Mechanism. The Journal of Biological Chemistry, 281, 9030-9037.
[65] Vander Heiden, M.G., Cantley, L.C. and Thompson, C.B. (2009) Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation. Science, 324, 1029-1033.
[66] Kim, J.W., Gao, P., Liu, Y.C., Semenza, G.L. and Dang, C.V. (2007) Hypoxia-Inducible Factor 1 and Dysregulated c-Myc Cooperatively Induce Vascular Endothelial Growth Factor and Metabolic Switches Hexokinase 2 and Pyruvate Dehydrogenase Kinase 1. Molecular and Cellular Biology, 27, 7381-7393.
[67] Kim, J.W., Tchernyshyov, I., Semenza, G.L. and Dang, C.V. (2006) HIF-1-Mediated Expression of Pyruvate Dehydrogenase Kinase: A Metabolic Switch Required for Cellular Adaptation to Hypoxia. Cell Metabolism, 3, 177-185.
[68] Dang, C.V. (2007) The Interplay between MYC and HIF in the Warburg Effect. Ernst Schering Foundation Symposium Proceedings, 2007, 35-53.
[69] Yeung, S.J., Pan, J. and Lee, M.H. (2008) Roles of p53, MYC and HIF-1 in Regulating Glycolysis—The Seventh Hallmark of Cancer. Cellular and Molecular Life Sciences, 65, 3981-3999.
[70] Hu, C.Y., Mohtat, D., Yu, Y., Ko, Y.A., Shenoy, N., Bhattacharya, S., et al. (2014) Kidney Cancer Is Characterized by Aberrant Methylation of Tissue-Specific Enhancers That Are Prognostic for Overall Survival. Clinical Cancer Research, 20, 4349-4360.
[71] Fath, D.M., Kong, X., Liang, D., Lin, Z., Chou, A., Jiang, Y., et al. (2006) Histone Deacetylase Inhibitors Repress the Transactivation Potential of Hypoxia-Inducible Factors Independently of Direct Acetylation of HIF-Alpha. The Journal of Biological Chemistry, 281, 13612-13619.
[72] Burroughs, S.K., Kaluz, S., Wang, D., Wang, K., Van Meir, E.G. and Wang, B. (2013) Hypoxia Inducible Factor Pathway Inhibitors as Anticancer Therapeutics. Future Medicinal Chemistry, 5, 553-572.
[73] Chau, N.M., Rogers, P., Aherne, W., Carroll, V., Collins, I., McDonald, E., et al. (2005) Identification of Novel Small Molecule Inhibitors of Hypoxia-Inducible Factor-1 That Differentially Block Hypoxia-Inducible Factor-1 Activity and Hypoxia-Inducible Factor-1Alpha Induction in Response to Hypoxic Stress and Growth Factors. Cancer Research, 65, 4918-4928.
[74] Tan, C., de Noronha, R.G., Roecker, A.J., Pyrzynska, B., Khwaja, F., Zhang, Z., et al. (2005) Identification of a Novel Small-Molecule Inhibitor of the Hypoxia-Inducible Factor 1 Pathway. Cancer Research, 65, 605-612.
[75] Welsh, S.J., Dale, A.G., Lombardo, C.M., Valentine, H., de la Fuente, M., Schatzlein, A., et al. (2013) Inhibition of the Hypoxia-Inducible Factor Pathway by a G-Quadruplex Binding Small Molecule. Scientific Reports, 3, Article No. 2799.
[76] Bertout, J.A., Majmundar, A.J., Gordan, J.D., Lam, J.C., Ditsworth, D., Keith, B., et al. (2009) HIF2Alpha Inhibition Promotes p53 Pathway Activity, Tumor Cell Death, and Radiation Responses. Proceedings of the National Academy of Sciences of the United States of America, 106, 14391-14396.
[77] Scheuermann, T.H., Li, Q., Ma, H.W., Key, J., Zhang, L., Chen, R., et al. (2013) Allosteric Inhibition of Hypoxia Inducible Factor-2 with Small Molecules. Nature Chemical Biology, 9, 271-276.
[78] Allison, S.J., Knight, J.R., Granchi, C., Rani, R., Minutolo, F., Milner, J., et al. (2014) Identification of LDH-A as a Therapeutic Target for Cancer Cell Killing via (i) p53/NAD(H)-Dependent and (ii) p53-Independent Pathways. Oncogenesis, 3, e102.
[79] Doherty, J.R. and Cleveland, J.L. (2013) Targeting Lactate Metabolism for Cancer Therapeutics. The Journal of Clinical Investigation, 123, 3685-3692.
[80] Kuiper, C., Molenaar, I.G., Dachs, G.U., Currie, M.J., Sykes, P.H. and Vissers, M.C. (2010) Low Ascorbate Levels Are Associated with Increased Hypoxia-Inducible Factor-1 Activity and an Aggressive Tumor Phenotype in Endometrial Cancer. Cancer Research, 70, 5749-5758.
[81] Flashman, E., Davies, S.L., Yeoh, K.K., Schofield, C.J. (2010) Investigating the Dependence of the Hypoxia-Inducible Factor Hydroxylases (Factor Inhibiting HIF and Prolyl Hydroxylase Domain 2) on Ascorbate and Other Reducing Agents. The Biochemical Journal, 427, 135-142.
[82] Tian, W., Wang, Y., Xu, Y., Guo, X., Wang, B., Sun, L., et al. (2014) The Hypoxia-Inducible Factor Renders Cancer Cells More Sensitive to Vitamin C-Induced Toxicity. The Journal of Biological Chemistry, 289, 3339-3351.
[83] Chen, .J, Zhao, S., Nakada, K., Kuge, Y., Tamaki, N., Okada, F., et al. (2003) Dominant-Negative Hypoxia-Inducible Factor-1Alpha Reduces Tumorigenicity of Pancreatic Cancer Cells through the Suppression of Glucose Metabolism. The American Journal of Pathology, 162, 1283-1291.
[84] Padayatty, S.J., Riordan, H.D., Hewitt, S.M., Katz, A., Hoffer, L.J. and Levine, M. (2006) Intravenously Administered Vitamin C as Cancer Therapy: Three Cases. CMAJ: Canadian Medical Association Journal, 174, 937-942.
[85] Rapisarda, A., Uranchimeg, B., Sordet, O., Pommier, Y., Shoemaker, R.H. and Melillo, G. (2004) Topoisomerase I-Mediated Inhibition of Hypoxia-Inducible Factor 1: Mechanism and Therapeutic Implications. Cancer Research, 64, 1475-1482.
[86] Lou, J.J., Chua, Y.L., Chew, E.H., Gao, J., Bushell, M. and Hagen, T. (2010) Inhibition of Hypoxia-Inducible Factor-1Alpha (HIF-1Alpha) Protein Synthesis by DNA Damage Inducing Agents. PLoS ONE, 5, e10522.
[87] Shin, D.H., Chun, Y.S., Lee, D.S., Huang, L.E. and Park, J.W. (2008) Bortezomib Inhibits Tumor Adaptation to Hypoxia by Stimulating the FIH-Mediated Repression of Hypoxia-Inducible Factor-1. Blood, 111, 3131-3136.
[88] Thomas, G.V., Tran, C., Mellinghoff, I.K., Welsbie, D.S., Chan, E., Fueger, B., et al. (2006) Hypoxia-Inducible Factor Determines Sensitivity to Inhibitors of mTOR in Kidney Cancer. Nature Medicine, 12, 122-127.
[89] Kondapaka, S.B., Singh, S.S., Dasmahapatra, G.P., Sausville, E.A. and Roy, K.K. (2003) Perifosine, a Novel Alkylphospholipid, Inhibits Protein Kinase B Activation. Molecular Cancer Therapeutics, 2, 1093-1103.
[90] Jayatunga, M.K., Thompson, S., McKee, T.C., Chan, M.C., Reece, K.M., Hardy, A.P., et al. (2015) Inhibition of the HIF1Alpha-p300 Interaction by Quinone- and Indandione-Mediated Ejection of Structural Zn(II). European Journal of Medicinal Chemistry, 94, 509-516.
[91] Wu, D., Zhang, R., Zhao, R., Chen, G., Cai, Y. and Jin, J. (2013) A Novel Function of Novobiocin: Disrupting the Interaction of HIF 1Alpha and p300/CBP through Direct Binding to the HIF1Alpha C-Terminal Activation Domain. PLoS ONE, 8, e62014.
[92] Cook, K.M., Hilton, S.T., Mecinovic, J., Motherwell, W.B., Figg, W.D. and Schofield, C.J. (2009) Epidithiodiketopiperazines Block the Interaction between Hypoxia-Inducible Factor-1Alpha (HIF-1Alpha) and p300 by a Zinc Ejection Mechanism. The Journal of Biological Chemistry, 284, 26831-26838.

Copyright © 2021 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.